alexa
Reach Us +1-217-403-9671
Development Of New Anticancer Agents | 7483
ISSN: 2167-7689

Pharmaceutical Regulatory Affairs: Open Access
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Development of new anticancer agents

2nd International Conference and Exhibition on Pharmaceutical Regulatory Affairs

Ahmed Kamal

Accepted Abstracts: Pharmaceut Reg Affairs

DOI: 10.4172/2167-7689.S1.008

Abstract
Cancer continues to be a major health concern and a number of deaths are caused by cancer that is second only to cardiovascular diseases. The development of compounds that target genes involved in cancer pathogenesis is a potential area of cancer drug discovery. A number of anticancer drugs employed clinically exert their effect by inhibiting nucleic acid (DNA or RNA) or protein synthesis. It is evident that DNA is an important cellular target for many anticancer agents. Pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) are naturally occurring compounds isolated from various Streptomyces species. The PBDs exert their biological activity through covalent binding within the minor groove of DNA. Several PBD conjugates have been synthesized to investigate the detailed biological aspects relating to the mechanism of action. Some of the potent molecules like PBD-quinazolinones and PBD-diaryloxadiazoles have been evaluated for their in vivo efficacy studies. These studies suggest that such PBD conjugates have promising anticancer activity. Some of the PBD conjugates act as activators of p53 and suppressors of NF-κB and thereby they could be considered as promising anticancer agents with improved potential for the suppression of tumours. To improve the selectivity as well as stability, some new β-galactoside prodrugs of PBDs have been synthesized and evaluated for their potential use in selective therapy of solid tumors by ADEPT and PMT protocols. Another important property of these molecules is their enhanced water solubility and stability, which are essential for a molecule to be an effective drug.
Biography
Ahmed Kamal graduated from Osmania University, Hyderabad (India) and did his Ph.D. research in the area of Medicinal Chemistry. He later joined as a Scientist at the Indian Institute of Chemical Technology (IICT), Hyderabad. For the last 25 years, he has pursued his research career at IICT, Hyderabad and is presently working as an Outstanding Scientist. He also holds an additional charge of Project Director of NIPER, Hyderabad. He has over 290 publications, 12 review papers and 7 book chapters and has filed over 75 patents. He is serving as an editorial advisory board member for the journals of repute.
Top